VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
VivoSim Labs, INC.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.16+0.00 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $825.22K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2026
Gross margin
100.0%
Operating margin
-8768.7%
Net margin
-10567.2%
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -9.0% | -29.3% | – | -21.5% | |
| Gross profit | -5.8% | – | – | -21.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -61.7% | -51.1% | -294.8% | |
| Return on assets | -56.2% | -49.2% | -125.6% | |
| Current ratio | 10.83 | 53.26 | 2.38 | |
| Interest coverage | – | – | -957.3× | |
| Inventory turnover | 2.2× | – | – | |
| Capex to revenue | 32.0% | – | 0.0% | |
| Diluted shares | 0M | 1M | 3M |
Where the cash went
Fiscal 2022 to 2026, five years combined
VivoSim Labs generated $55.80M from operations and spent $860.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$55.80M
Used
$860.00K
Capital expenditure$860.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-10567.2%
×Asset turnover0.01×
×Equity multiplier2.35×
=Return on equity, FY2026-294.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -10567.2% | 0.01× | 2.35× | -294.8% |
| FY2025 | -1727.8% | 0.01× | 1.49× | -35.3% |
| FY2024 | -13459.6% | 0.01× | 1.41× | -155.0% |
| FY2023 | -4664.6% | 0.01× | 1.18× | -75.8% |
| FY2022 | -763.2% | 0.04× | 1.05× | -33.0% |
| FY2020 | -852.0% | 0.06× | 1.10× | -59.5% |
| FY2019 | -861.7% | 0.07× | 1.12× | -65.9% |
| FY2018 | -756.1% | 0.08× | 1.11× | -65.1% |
| FY2017 | -908.9% | 0.06× | 1.10× | -61.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$13.84M
- Cash generatingOperating cash flow above zero-$10.83M
- Return on assets improvedROA up on the prior year-39.2% → -94.5%
- Earnings backed by cashOperating cash flow above net income-$10.83M vs -$13.84M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.25 → 2.38
- No dilutionShare count did not rise1M → 3M
- Gross margin improvedGross margin up on the prior year96.53% → 100.00%
- More efficientAsset turnover rose0.02 → 0.01